Total Funding
8
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
AndroBioSys is a biotechnology company that focuses on the development of novel treatments for prostate disease.
James L. Mohler: CMO
Gary J. Smith: CSO
About the Company
AndroBioSys, Inc. (ABS), is a biotechnology company dedicated to the development of novel treatments for prostate disease. Based on technologies developed at Roswell Park Cancer Institute, AndroBioSys is pioneering new approaches to make treatment of prostate cancer curative, not palliative. Preventing progression of prostate disease is intertwined
intimately with disruption of the androgen axis. ABS performs contract research screening services for academic, biotechnology and pharmaceutical clients and develops collaborative partnerships to discover new drugs to proprietary prostate disease targets.
